Last reviewed · How we verify
native L asparaginase
At a glance
| Generic name | native L asparaginase |
|---|---|
| Sponsor | ERYtech Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children (PHASE3)
- Erwinase Master Treatment Protocol
- Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (PHASE3)
- GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia (PHASE2, PHASE3)
- A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy (PHASE2)
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia (PHASE3)
- Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |